TAP Uprima
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
TAP will meet with FDA in the first quarter to discuss resubmission of the NDA for the erectile dysfunction agent apomorphine. The company withdrew the Uprima NDA in June due to safety concern